Detalhe da pesquisa
1.
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Cancer Discov
; 12(6): 1500-1517, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35404998
2.
JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors.
J Med Chem
; 65(24): 16173-16203, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399068